Shoulder Innovations, Inc.

NYSE:SI

Medical - Specialties

Healthcare
$20.65 -0.72%

-$0.13 today

Market cap
$432.04M
Beta
-1.07
P/E (TTM)
-8.4
EPS (TTM)
-$2.13
52W Low $10.92High $19.79

Volume 0.09M

Average 0.10M

SI EBITDA Margin

EBITDA as a percentage of revenue.

Shoulder Innovations, Inc.NYSE: SI

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -46.0%

EBITDA Margin was -46.0% in Q1 FY2026, down 10.2 pp from a year earlier. On a trailing-twelve-month basis it was -76.3%, down 35.4 pp year over year.

Context

  • EBITDA Margin widened in 1 of the last 2 fiscal years.
  • FY2025 was the lowest level in the 3 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -42.7% for the fiscal year ending Dec 2026, up from -78.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-46.0%+5.2 pp QoQ
Last fiscal yearDec 2025
-78.4%-40.1 pp YoY
LTMMar 2026
-76.3%-35.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-10.2 pp+115.0 pp+125.1 pp
1 year-40.1 pp+35.6 pp+75.7 pp
3 years—+57.0 pp—
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-78.4%
Year-over-year change
-40.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SI compares with its peers on the latest reported figures

  • SI's LTM Mar 2026 EBITDA Margin of -76.3% is the 7th highest of the 8 companies compared; the peer median is -13.0%.
  • Its year-over-year change of -35.4 pp is the lowest of 8, against a peer median of +16.3 pp.
SI Competitors Peer median
EBITDA Margin for SI and competitors
Company Period LTM level YoY 3-year change
SNWVSANUWAVE Health, Inc.LTM Mar 202651.1% +104.6 pp+15.5 pp
INGNInogen, Inc.LTM Mar 2026-1.5% +0.6 pp+1.8 pp
ASMBAssembly Biosciences, Inc.LTM Mar 2026-8.8% +113.4 pp—
MDXHMDxHealth S.A.FY2025-13.0% +11.5 pp+85.2 pp
OMOutset Medical, Inc.LTM Mar 2026-53.0% +16.3 pp+80.2 pp
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-67.3% +67.9 pp+30.0 pp
SIShoulder Innovations, Inc.LTM Mar 2026-76.3% -35.4 pp—
NNOXNano-X Imaging Ltd.LTM Dec 2025-376.3% +15.0 pp+506.1 pp
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
AARDAardvark Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding SI) -13.0%+16.3 pp+55.1 pp

Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.27M31.62M47.32M
Cost of Revenue4M7.28M11.12M
Gross Profit15.27M24.34M36.2M
Gross Margin79.2%77.0%76.5%
Research & Development3.02M4.49M7.73M
Selling, General & Admin23.11M34.51M54.77M
Operating Expenses26.13M38.99M62.5M
Depreciation & Amortization1.64M2.2M3.21M
EBITDA(10.25M)(12.11M)(37.08M)
EBITDA Margin-53.2%-38.3%-78.4%
Operating Income(10.86M)(14.65M)(26.3M)
Operating Margin-56.4%-46.3%-55.6%
Interest Income000
Interest Expense761K1.32M70K
Other Income / Expenses(1.79M)(966K)(14.06M)
Income Before Tax(12.66M)(15.62M)(40.36M)
Pre-Tax Margin-65.7%-49.4%-85.3%
Income Tax Expense000
Net Income(12.66M)(15.62M)(40.36M)
Net Margin-65.7%-49.4%-85.3%
EPS (Basic)(0.63)(0.77)(1.96)
EPS (Diluted)(0.63)(0.77)(1.96)
Weighted Avg Shares19.92M19.92M20.63M
Weighted Avg Shares (Diluted)19.92M19.92M20.63M

Shoulder Innovations, Inc.

NYSE:SI

Intrinsic Alpha fair value

Locked

Current Price

$20.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.